X4 Pharmaceuticals, Inc

X4 Pharmaceuticals announced the appointment of Kelly Gold to its Board of Directors, effective July 1, 2026. Ms. Gold will serve as an independent director and a member of the Audit Committee, bringing significant financial leadership, capital markets expertise, and a scientific background. The company expects her experience as a public company CFO and deep understanding of the biotech landscape to be valuable as it progresses mavorixafor towards potential approval and commercialization.

X4 Pharmaceuticals announced that it issued inducement awards to new employees, effective May 29, 2026. These awards consist of options to purchase an aggregate of 160,000 shares of the company's common stock under the 2019 Inducement Equity Incentive Plan. The options have an exercise price of $4.31 per share, a ten-year term, and vest over a four-year period, with 25% vesting after 12 months and the remainder monthly over the subsequent 36 months, subject to continued employment.

X4 Pharmaceuticals, Inc. announced the final results of its Annual Meeting of Stockholders. Stockholders elected three Class III director nominees, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and approved the Second Amended and Restated 2017 Equity Incentive Plan. Additionally, the non-binding advisory vote on the compensation of named executive officers was approved.

X4 Pharmaceuticals reported its first-quarter 2026 financial results and provided a corporate update. The European Commission granted marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome in the EU, and the global 4WARD Phase 3 chronic neutropenia trial remains on track to complete enrollment by the end of Q3 2026. The company's cash position of $233.7 million as of March 31, 2026, provides a cash runway through 2028. For Q1 2026, X4 Pharmaceuticals reported a net loss of $(20.2) million on total revenue of $2.7 million, compared to a net income of $0.3 million on $28.8 million revenue in Q1 2025, primarily due to a one-time license revenue in the prior year.

X4 Pharmaceuticals reported a net loss of $(20.2) million for Q1 2026, a significant decline from a net income of $0.3 million in Q1 2025. Total revenue decreased by 90.6% to $2.7 million, primarily due to a large license payment in the prior year, though product revenue increased. The company continues its Phase 3 clinical trial for mavorixafor in chronic neutropenia and maintains sufficient liquidity for the next 12 months.